These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36476642)

  • 1. Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines.
    Krasavin M; Adamchik M; Bubyrev A; Heim C; Maiwald S; Zhukovsky D; Zhmurov P; Bunev A; Hartmann MD
    Eur J Med Chem; 2023 Jan; 246():114990. PubMed ID: 36476642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational investigations of indanedione and indanone derivatives in drug discovery: Indanone derivatives inhibits cereblon, an E3 ubiquitin ligase component.
    Nayek U; Basheer Ahamed SI; Mansoor Hussain UH; Unnikrishnan MK; Abdul Salam AA
    Comput Biol Chem; 2022 Dec; 101():107776. PubMed ID: 36252444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
    Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
    J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
    Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
    J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
    Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
    FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligands for cereblon: 2017-2021 patent overview.
    Kazantsev A; Krasavin M
    Expert Opin Ther Pat; 2022 Feb; 32(2):171-190. PubMed ID: 34704527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of novel cereblon modulators and their target molecules].
    Ito T
    Rinsho Ketsueki; 2022; 63(6):573-579. PubMed ID: 35831190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein degraders - from thalidomide to new PROTACs.
    Ito T
    J Biochem; 2024 Apr; 175(5):507-519. PubMed ID: 38140952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cereblon -  a new target of therapy in the treatment of multiple myeloma].
    Staňková M; Bešše L; Sedlaříková L; Vrábel D; Hájek R; Sevčíková S
    Klin Onkol; 2014; 27(5):326-30. PubMed ID: 25312709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and characterization of potent spiro-isoxazole-based cereblon ligands with a novel binding mode.
    Shevalev R; Bischof L; Sapegin A; Bunev A; Olga G; Kantin G; Kalinin S; Hartmann MD
    Eur J Med Chem; 2024 Apr; 270():116328. PubMed ID: 38552426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Thalidomide, cereblon and multiple myeloma].
    Ogura T
    Nihon Rinsho; 2015 Jan; 73(1):149-55. PubMed ID: 25626321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation.
    Xie H; Li C; Tang H; Tandon I; Liao J; Roberts BL; Zhao Y; Tang W
    J Med Chem; 2023 Feb; 66(4):2904-2917. PubMed ID: 36749666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Highly Potent CRBN Ligands and Insight into Their Binding Mode through Molecular Docking and Molecular Dynamics Simulations.
    Yan J; Zheng Z
    ChemMedChem; 2023 Mar; 18(5):e202200573. PubMed ID: 36750890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation.
    Nie X; Zhao Y; Tang H; Zhang Z; Liao J; Almodovar-Rivera CM; Sundaresan R; Xie H; Guo L; Wang B; Guan H; Xing Y; Tang W
    Chembiochem; 2024 Feb; 25(4):e202300685. PubMed ID: 38116854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders.
    Yamamoto J; Ito T; Yamaguchi Y; Handa H
    Chem Soc Rev; 2022 Aug; 51(15):6234-6250. PubMed ID: 35796627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
    Chamberlain PP; Lopez-Girona A; Miller K; Carmel G; Pagarigan B; Chie-Leon B; Rychak E; Corral LG; Ren YJ; Wang M; Riley M; Delker SL; Ito T; Ando H; Mori T; Hirano Y; Handa H; Hakoshima T; Daniel TO; Cathers BE
    Nat Struct Mol Biol; 2014 Sep; 21(9):803-9. PubMed ID: 25108355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology.
    Ito T; Yamaguchi Y; Handa H
    Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs.
    Min J; Mayasundari A; Keramatnia F; Jonchere B; Yang SW; Jarusiewicz J; Actis M; Das S; Young B; Slavish J; Yang L; Li Y; Fu X; Garrett SH; Yun MK; Li Z; Nithianantham S; Chai S; Chen T; Shelat A; Lee RE; Nishiguchi G; White SW; Roussel MF; Potts PR; Fischer M; Rankovic Z
    Angew Chem Int Ed Engl; 2021 Dec; 60(51):26663-26670. PubMed ID: 34614283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lys-63-specific deubiquitinase BRCC36 enhances the sensitivity of multiple myeloma cells to lenalidomide by inhibiting lysosomal degradation of cereblon.
    Wang B; Li M; Cao D; Sun Q; Yu W; Ma J; Ren H; Xu G; Zhou L
    Cell Mol Life Sci; 2024 Aug; 81(1):349. PubMed ID: 39136771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
    Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
    Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.